Last edition
News about
Anteris Technologies Global Corp. Begins US Enrollment in PARADIGM Trial for DurAVR Heart Valve
Anteris marks first patients successfully treated in US as global trial evaluates safety and effectiveness of DurAVR THV against existing transcatheter aortic valve therapies.
Viralgen Partners with Elaaj Bio to Advance Gene Therapy for CDKL5 Deficiency Disorder
Viralgen partners with Elaaj Bio to advance an AAV-based gene therapy program for CDKL5 Deficiency Disorder, leveraging specialised manufacturing expertise.
Altesa BioSciences Initiates Phase IIb CARDINAL Trial for COPD Treatment
Altesa BioSciences begins global CARDINAL trial to assess antiviral vapendavir for improving symptoms and lung function in COPD patients.
Merck Completes USD 5.8 Billion Acquisition of Terns Pharmaceuticals to Strengthen Oncology Pipeline
Merck acquires Terns Pharmaceuticals, advancing development of next-generation therapies for chronic myeloid leukaemia.
Alloy Therapeutics and IPI Partners to Advance Next-Gen Antibody Discovery
Alloy Therapeutics and IPI collaborate to develop advanced VHH libraries for faster, more efficient next-generation antibody discovery.
Eli Lilly and Company's Omvoh Shows 4-Year Disease Clearance in Ulcerative Colitis
Eli Lilly and Company’s Omvoh (mirikizumab-mrkz), the first IL-23p19 inhibitor, shows durable disease clearance in ulcerative colitis, with more than 60 percent of patients maintaining remission through 4 years in the LUCENT-3 study.
Anuh Pharma Gets Prequalification Nod from WHO for Anti-Malarial Bulk Drug
Anuh Pharma receives World Health Organization (WHO) prequalification for Amodiaquine Hydrochloride API, an essential anti-malarial medicine used in combination therapies for Plasmodium falciparum malaria.
Cellenkos Receives US FDA IND Clearance for CK0802 Phase 1b/ 2a Trial in GVHD
The US Food and Drug Administration (FDA) clears Cellenkos Inc IND for CK0802, a first-in-class off-the-shelf Treg therapy, advancing to a phase 1b/2a trial in steroid-refractory Graft-Versus-Host Disease (GVHD).
Amgen Adds USD 300 Million to US Manufacturing, Total Nears USD 2 Billion
Amgen invests an additional USD 300 Million in US manufacturing, bringing total investment to nearly USD 2 Billion to strengthen supply chain resilience, and next-generation technology.
Converge Bio Uses ConvergeAB to Enhance Cancer Treatment
Converge Bio uses its ConvergeAB AI platform to enhance cetuximab, achieving 2x higher receptor binding affinity and improved cancer signal blocking, with findings supporting a provisional patent filing.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy